Figure 3.

Experimental treatment schedules and therapeutic effects of NK-HD cells in combination with Bev plus Iri estimated in the s.c U87 mouse model. At a tumor size of 100 mm³, the mice were treated with Bev and Iri every 7 days for 14 days. NK-HD cells were injected after 1 day of Bev and Iri treatment (A). The mouse weight before and after the treatment with NK-HD cells in combination with Bev and Iri was clarified every 9 days (B). The tumor size before and after the treatment with NK-HD cells in combination with Bev and Iri was clarified every 9 days and the tumor volume was calculated as follows: V = 4/3π (length × width × height/8) (C–E). The Kaplan–Meier survival of U87-bearing mice of control, NK-IV^lo, Bev plus Iri^hi, and NK-IV^lo in combination with Bev plus Iri^hi group was estimated. The statistical significance of survival was determined using a log-rank test with Bonferroni correction applied for comparisons (F). NK-IV^lo: intravenously injected NK-HD cells (1 × 10⁷ NK cells); Bev+Iri^hi: intraperitoneally injected bevacizumab (10 mg/kg) plus irinotecan (125 mg/m²); U87: human GBM cell line. All data are shown as mean ± SD. p< 0.05 (*). n.s, no significant difference.